OCS — Oculis Holding AG

Nasdaq · Health Care · Pharmaceuticals · CIK 1953530 ·
Last close
$29.93
Market Cap
$1.81B
52W High
$34.47
52W Low
$24.02
ADV30
463,373
Next earnings
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -21,728,000 -28,852,000 243,993,000 64,564,000 47,345,000
Dec 2025 0 -20,633,000 -23,514,000 235,963,000 81,329,000 39,893,000
Sep 2025 0 -20,296,000 -16,855,000 167,836,000 46,440,000 37,242,000
Jun 2025 0 -20,768,000 -25,375,000 181,621,000 64,265,000 38,525,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-66,304,000
Investing CF
$-60,934,000
Financing CF
$186,918,000
CapEx
$-1,388,000
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-1.92
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-384,514,000
Inventory
Receivables
$1,794,000
ST Investments
$131,684,000
EBIT TTM
$-98,310,000
Pretax Income TTM
$-99,143,000
Interest Exp TTM
$833,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,123,000
EBITDA
$-83,359,000
Free Cash Flow
Enterprise Value
$1,516,633,344
Total Cash
$222,034,000
Total Debt
$2,248,000
Shares Out
60,388,073
Trailing EPS
$-2.15
Book Value
$4.32
ROE
-52.7%
ROA
-23.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -81,672,000 -98,957,000 235,963,000 39,893,000 -66,304,000
Dec 2024 0 -73,204,000 -85,777,000 120,353,000 46,970,000 -48,919,000
Dec 2023 0 -45,851,000 -88,802,000 114,353,000 20,625,000 -55,037,000
Dec 2022 0 -32,376,000 -38,698,000 37,060,000 135,051,000 -25,074,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.09

Peers — same industry

TickerNameMarket CapLastDaily %
GLPG Lakefront Biotherapeutics NV $1.81B $27.49
OCUL OCULAR THERAPEUTIX, INC $1.82B $8.29
NRIX Nurix Therapeutics, Inc. $1.80B $17.38
GLPGF Lakefront Biotherapeutics NV $1.85B $28.08
ANIP ANI PHARMACEUTICALS INC $1.85B $81.41

News headlines (Yahoo Finance, 1h cache)

Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls
2026-05-21 13:40 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-05-15 20:05 · Yahoo
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
2026-05-14 20:05 · Yahoo
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
2026-05-11 22:05 · Yahoo
Oculis Reports Q1 2026 Financial Results and Provides Company Update
2026-05-11 20:07 · Yahoo
Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains
2026-05-11 05:09 · Yahoo
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
2026-05-07 09:00 · Yahoo
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
2026-05-06 12:25 · Yahoo
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
2026-05-05 08:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.